Published in Mol Cancer Res on March 01, 2007
Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res (2008) 1.80
Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res (2008) 1.52
SOCS proteins in development and disease. Am J Clin Exp Immunol (2013) 1.17
The enigmatic cytokine oncostatin m and roles in disease. ISRN Inflamm (2013) 1.01
Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol (2011) 1.00
Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. BMC Cancer (2010) 0.88
Low expression of SOCS-1 and SOCS-3 is a poor prognostic indicator for gastric cancer patients. J Cancer Res Clin Oncol (2014) 0.83
CUEDC2 (CUE domain-containing 2) and SOCS3 (suppressors of cytokine signaling 3) cooperate to negatively regulate Janus kinase 1/signal transducers and activators of transcription 3 signaling. J Biol Chem (2011) 0.83
The role of suppressors of cytokine signalling in human neoplasms. Mol Biol Int (2014) 0.81
Estradiol and Estrogen Receptor Agonists Oppose Oncogenic Actions of Leptin in HepG2 Cells. PLoS One (2016) 0.78
JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer. Mol Cancer Ther (2017) 0.75
Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J (2003) 10.77
Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice. J Dtsch Dermatol Ges (2011) 2.82
Fibulin-5 mutations link inherited neuropathies, age-related macular degeneration and hyperelastic skin. Brain (2011) 2.15
Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chem Biol (2011) 2.05
IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J (2003) 2.00
Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol (2003) 1.92
Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res (2010) 1.90
Naevus lentiginosus linearis: A distinct skin disorder. Acta Derm Venereol (2010) 1.80
Hepatic acute phase proteins--regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. Eur J Cell Biol (2011) 1.71
RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. J Invest Dermatol (2011) 1.60
A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol (2007) 1.59
Intrahepatic synthesis of tumor necrosis factor-alpha related to cardiac surgery is inhibited by interleukin-10 via the Janus kinase (Jak)/signal transducers and activator of transcription (STAT) pathway. Crit Care Med (2003) 1.56
Hydroxychloroquine modulates metabolic activity and proliferation and induces autophagic cell death of human dermal fibroblasts. J Invest Dermatol (2009) 1.55
Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol (2004) 1.52
Jaks and cytokine receptors--an intimate relationship. Biochem Pharmacol (2006) 1.50
A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. J Immunol Methods (2006) 1.50
SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem (2002) 1.48
Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair. Nat Cell Biol (2002) 1.48
Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol (2007) 1.46
Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol (2013) 1.44
Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol (2006) 1.43
Real time analysis of STAT3 nucleocytoplasmic shuttling. J Biol Chem (2003) 1.38
New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci (2003) 1.37
Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol (2003) 1.36
Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood (2005) 1.34
Nucleocytoplasmic shuttling of persistently activated STAT3. J Cell Sci (2007) 1.31
Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction. J Immunol (2002) 1.29
Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol (2010) 1.28
Regulation of suppressor of cytokine signaling 3 (SOCS3) mRNA stability by TNF-alpha involves activation of the MKK6/p38MAPK/MK2 cascade. J Immunol (2007) 1.27
Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc (2011) 1.27
Frontiers in sebaceous gland biology and pathology. Exp Dermatol (2008) 1.27
Ichthyosis, follicular atrophoderma, and hypotrichosis caused by mutations in ST14 is associated with impaired profilaggrin processing. J Invest Dermatol (2008) 1.26
Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J Biol Chem (2003) 1.25
Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol (2004) 1.25
Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo. FASEB J (2003) 1.22
Advanced glycation end products: Key players in skin aging? Dermatoendocrinol (2012) 1.20
Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res (2004) 1.20
Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med (2010) 1.19
Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci (2005) 1.18
Cross-regulation of cytokine signalling: pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation. J Cell Sci (2010) 1.17
Dimerization of the cytokine receptors gp130 and LIFR analysed in single cells. J Cell Sci (2005) 1.16
Identification of the critical sequence elements in the cytoplasmic domain of leptin receptor isoforms required for Janus kinase/signal transducer and activator of transcription activation by receptor heterodimers. Mol Endocrinol (2002) 1.16
Interleukin-6 is a direct mediator of T cell migration. Eur J Immunol (2004) 1.13
Neurophysiology of pruritus: cutaneous elicitation of itch. Arch Dermatol (2003) 1.12
A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. Eur J Biochem (2002) 1.12
Interleukin-6 regulates hepatic transporters during acute-phase response. Biochem Biophys Res Commun (2004) 1.11
Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol (2004) 1.11
Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc (2011) 1.10
The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. J Biol Chem (2005) 1.10
Alpha-melanocyte-stimulating hormone counteracts the suppressive effect of UVB on Nrf2 and Nrf-dependent gene expression in human skin. Endocrinology (2009) 1.10
Long term association of the cytokine receptor gp130 and the Janus kinase Jak1 revealed by FRAP analysis. J Biol Chem (2003) 1.10
Characterization of the signaling capacities of the novel gp130-like cytokine receptor. J Biol Chem (2004) 1.09
Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. Carcinogenesis (2005) 1.09
The matrix metalloproteinase 9 (mmp-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist. J Biol Chem (2002) 1.08
Processing of procollagen III by meprins: new players in extracellular matrix assembly? J Invest Dermatol (2010) 1.07
Interleukin-27 displays interferon-gamma-like functions in human hepatoma cells and hepatocytes. Hepatology (2009) 1.07
New target genes of MITF-induced microRNA-211 contribute to melanoma cell invasion. PLoS One (2013) 1.06
alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma? Arthritis Rheum (2009) 1.06
A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol (2006) 1.06
Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: unraveling the peeling skin disease. Am J Hum Genet (2010) 1.05
Successful treatment of generalized eruptive histiocytoma with PUVA. J Dtsch Dermatol Ges (2007) 1.05
Increased cAMP levels modulate transforming growth factor-beta/Smad-induced expression of extracellular matrix components and other key fibroblast effector functions. J Biol Chem (2009) 1.04
Akt modulates STAT3-mediated gene expression through a FKHR (FOXO1a)-dependent mechanism. J Biol Chem (2002) 1.04
Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients. J Cutan Pathol (2009) 1.03
Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases. Mol Cancer Res (2007) 1.02
Novel role of Janus kinase 1 in the regulation of oncostatin M receptor surface expression. J Biol Chem (2002) 1.01
Neuroendocrine regulation of sebocytes -- a pathogenetic link between stress and acne. Exp Dermatol (2004) 1.01
Interferon-γ-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. Cell Commun Signal (2012) 1.00
Indeterminate cell histiocytosis: fact or fiction? J Cutan Pathol (2005) 1.00
STAT3 is enriched in nuclear bodies. J Cell Sci (2003) 1.00
Mammary gland remodeling depends on gp130 signaling through Stat3 and MAPK. J Biol Chem (2004) 1.00
The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling. Biochem J (2004) 0.98
Mechanisms of SOCS3 phosphorylation upon interleukin-6 stimulation. Contributions of Src- and receptor-tyrosine kinases. J Biol Chem (2005) 0.98
Multiple reasons for an inefficient STAT1 response upon IL-6-type cytokine stimulation. Cell Signal (2005) 0.97
Immune response modifiers--mode of action. Exp Dermatol (2006) 0.97
Orientational constraints of the gp130 intracellular juxtamembrane domain for signaling. J Biol Chem (2002) 0.97
Evidence for expression of melanocortin-1 receptor in human sebocytes in vitro and in situ. J Invest Dermatol (2002) 0.97
Surgical treatment of persistent macrocheilia in patients with Melkersson-Rosenthal syndrome and cheilitis granulomatosa. Arch Dermatol (2005) 0.97
Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cells. J Biol Chem (2003) 0.96
STAT5 contributes to interferon resistance of melanoma cells. Curr Biol (2005) 0.96
Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritis. Exp Dermatol (2005) 0.96
Hypoxia-inducible factor 1alpha is up-regulated by oncostatin M and participates in oncostatin M signaling. Hepatology (2009) 0.96
Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. J Immunol (2008) 0.95